Drugs / PF-04691502
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00927823 | Dec 2009 → Mar 2011 | cancer | Pfizer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01658176 | Jan 2013 → Apr 2015 | breast neoplasm | Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT01430585 | Mar → Dec 2012 | breast cancer | Pfizer | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-04691502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01430585 ↗ |
| Known as | PF-4691502 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1234354 ↗ |
| Action | Inhibit | “PI3K/MTOR inhibitor” NCT00927823 ↗ |
| Modality | Small molecule | — CHEMBL1234354 ↗ |
| Route | Oral | “PF-04691502 administered orally at 8 mg as a continuous daily dosing schedule” NCT01658176 ↗ |
| Target | MTOR | “PI3K/MTOR inhibitor” NCT00927823 ↗ |